Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001401914-24-000041
Filing Date
2024-11-14
Accepted
2024-11-14 16:01:39
Documents
62
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q dare-20240930.htm   iXBRL 10-Q 1072704
2 EX-31.1 exhibit311_20240930.htm EX-31.1 15303
3 EX-32.1 exhibit321_20240930.htm EX-32.1 4265
9 dare-20240930_g1.jpg GRAPHIC 130914
  Complete submission text file 0001401914-24-000041.txt   6356954

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dare-20240930.xsd EX-101.SCH 59636
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dare-20240930_cal.xml EX-101.CAL 46077
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dare-20240930_def.xml EX-101.DEF 288239
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dare-20240930_lab.xml EX-101.LAB 666566
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dare-20240930_pre.xml EX-101.PRE 451181
65 EXTRACTED XBRL INSTANCE DOCUMENT dare-20240930_htm.xml XML 567915
Mailing Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122
Business Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122 858-926-7655
Dare Bioscience, Inc. (Filer) CIK: 0001401914 (see all company filings)

EIN.: 204139823 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36395 | Film No.: 241461562
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)